Drug Patent Expirations in November 2013

Drug Patent Expirations in November 2013

Drug Patent Expirations for November 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
SAMSCA Otsuka America Pharm tolvaptan 5,258,510 Nov 2, 2013
PROPECIA Merck finasteride 5,571,817 Nov 5, 2013
ACIPHEX SPRINKLE Eisai Inc rabeprazole sodium 5,045,552*PED Nov 8, 2013
ACIPHEX Eisai Inc rabeprazole sodium 5,045,552*PED Nov 8, 2013
TECHNESCAN MAG3 Mallinckrodt technetium tc-99m mertiatide kit 5,573,748 Nov 12, 2013
EXPAREL Pacira Pharms Inc bupivacaine 6,132,766 Nov 16, 2013
SURFAXIN Discovery Labs lucinactant 5,407,914 Nov 17, 2013
SUSTIVA Bristol Myers Squibb efavirenz 5,519,021*PED Nov 21, 2013
ATRIPLA Gilead efavirenz; emtricitabine; tenofovir disoproxil fumarate 5,519,021*PED Nov 21, 2013
JEVTANA KIT Sanofi Aventis Us cabazitaxel 5,438,072 Nov 22, 2013
CHILDREN'S ALLEGRA ALLERGY Sanofi Aventis Us fexofenadine hydrochloride 5,578,610 Nov 26, 2013
ALINIA Romark nitazoxanide 5,578,621 Nov 26, 2013
CHILDREN'S ALLEGRA HIVES Sanofi Aventis Us fexofenadine hydrochloride 5,578,610 Nov 26, 2013
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 5,578,610 Nov 26, 2013
ZOLINZA Merck vorinostat RE38506 Nov 29, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.